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Abstract
Background: Glycogen Synthase Kinase-3 (GSK3) activity is repressed following insulin treatment
of cells. Pharmacological inhibition of GSK3 mimics the effect of insulin on Phosphoenolpyruvate
Carboxykinase (PEPCK), Glucose-6 Phosphatase (G6Pase) and IGF binding protein-1 (IGFBP1)
gene expression. CAAT/enhancer binding protein alpha (C/EBPα) regulates these gene promoters
in liver and is phosphorylated on two residues (T222/T226) by GSK3, although the functional
outcome of the phosphorylation has not been established. We aimed to establish whether CEBPα
is a link between GSK3 and these gene promoters.
Results:  C/EBPα represses the IGFBP1 thymine-rich insulin response element (TIRE), but
mutation of T222 or T226 of C/EBPα to non-phosphorylatable alanines has no effect on C/EBPα
activity in liver cells (towards the TIRE or a consensus C/EBP binding sequence). Phosphorylation
of T222/T226 is decreased by GSK3 inhibition, suggesting GSK3 does phosphorylate T222/226 in
intact cells. However, phosphorylation was not altered by treatment of liver cells with insulin.
Meanwhile C/EBPα activity in 3T3 L1 preadipocytes was enhanced by mutation of T222/T226 and/
or S230 to alanine residues. Finally, we demonstrate that C/EBPα is a very poor substrate for GSK3
in vitro and in cells.
Conclusion: The work demonstrates an important role for this domain in the regulation of C/
EBPα activity in adipocytes but not hepatocytes, however GSK3 phosphorylation of these residues
does not mediate regulation of this C/EBP activity. In short, we find no evidence that C/EBPα
activity is regulated by direct phosphorylation by GSK3.
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Background
Glycogen synthase kinase-3 (GSK3), an insulin-inhibited
protein kinase, has been linked to the control of many cel-
lular processes [1]. It was originally identified as the pro-
tein kinase that phosphorylated and inactivated glycogen
synthase in rabbit muscle [2]. Two highly related forms of
GSK3 (GSK3α and GSK3β) are expressed from distinct
genes [3,4]. They share greater than 95% identity in their
kinase domains and appear to be ubiquitously expressed
in mammals [3,4]. In resting cells GSK3 activity is high
and inhibition of the kinase is achieved by at least two
mechanisms, firstly through phosphorylation of an N-ter-
minal serine residue (Ser-21 in GSK3α, Ser-9 in GSK3β)
[5,6], and secondly through protein protein interaction
[7]. Insulin promotes the phosphorylation of Ser-9/21 of
GSK3 by activation of protein kinase B (PKB, also known
as c-AKT) [8], while canonical wnt signalling inhibits
GSK3 independently of this N-terminal phosphorylation
[9].
In liver, inhibition of GSK3 reduces expression of the
Phosphoenolpyruvate Carboxykinase (PEPCK) and Glu-
cose-6 Phosphatase (G6Pase) genes, two rate limiting
enzymes in hepatic glucose production [10], as well as the
IGF binding protein-1 (IGFBP1) gene [11]. These gene
promoters share a related DNA sequence termed the
thymine-rich insulin response element (TIRE) that plays
an important role in their response to insulin [12-14].
Expression of these genes as well as GSK3 activity is abnor-
mally high in insulin resistant states such as Type 2 diabe-
tes mellitus (T2DM) [15-19]. Meanwhile overexpression
of GSK3 antagonises insulin regulation of IGFBP1 [11].
Therefore inhibition of GSK3 is proposed as a potential
target for the treatment of T2DM [1,20,21]. Indeed selec-
tive GSK3 inhibitors significantly reduce hepatic glucose
output and blood glucose levels in several animal models
of obesity and diabetes [22-25]. However, GSK3 is
reported to have over 30 substrates, and mutation of one
of these, APC, is linked to the development of colonic can-
cer [20,21,26]. In addition, genetic deletion of one of the
isoforms (GSK3β) leads to liver cell death, possibly due to
increased sensitivity to TNFα [27]. Hence great care and
consideration is being given to the development of GSK3
inhibitors for use in humans. With this in mind we have
initiated a search for molecules that link GSK3 to the glu-
coneogenic gene promoters and in particular the TIRE,
since inhibition of GSK3 is sufficient to repress the iso-
lated DNA element [11]. Identification of the GSK3 sub-
strate(s) that regulates IGFBP1, G6Pase and PEPCK gene
expression, may permit manipulation of this specific
interaction without affecting other GSK3 targets, thereby
reducing potential side effects. GSK3 is an unusual kinase
in that most substrates must be phosphorylated (primed)
on a Ser/Thr four or five residues C-terminal to the GSK3
target residue (see [1] for review). Priming of the substrate
is performed by a distinct protein kinase, therefore inhibi-
tion of the priming kinase indirectly inhibits GSK3 regu-
lation of the substrate, but only those substrates primed
by that particular priming kinase. Priming kinases are
potential targets for more specific interference with GSK3
function.
The basic leucine zipper transcription factor, CAAT-
enhancer binding protein alpha (C/EBPα) is a potential
link between GSK3 and the gluconeogenic genes based on
the following information in the literature; 1) C/EBPα is
phosphorylated on two residues (T222 and T226, num-
bers refer to rodent sequence) by GSK3, although the
functional effect of phosphorylation is not yet clear [28],
2) C/EBPα is a key molecule in the regulation of the
PEPCK and G6Pase gene promoters by cAMP [29-33] and
T3 [34], 3) C/EBPα is regulated by wnt [35] and insulin
[36,37] in brown adipocytes, and the insulin regulation
involves PKB (a regulator of GSK3) [37], 4) PEPCK and
G6Pase expression, as well as glucose and glycogen
metabolism is abnormal in animals lacking C/EBPα [38-
40] and 5) binding of a TIRE-interacting protein is
blocked using an oligonucleotide representing a known
C/EBPα binding sequence [41].
Therefore, we attempted to determine whether C/EBPα
could modulate the activity of the isolated TIRE, or the
gene promoters of interest, in a GSK3 regulated manner.
In addition, although T222/T226 of C/EBPα were identi-
fied as targets for GSK3 it has not previously been estab-
lished whether S230 was a target for a 'priming' kinase, so
we have also investigated whether mutation of S230 influ-
ences C/EBPα regulation.
Results and discussion
C/EBPα regulates the TIRE independently of T222/226 
phosphorylation
We have previously shown that insulin, or pharmacologi-
cal inhibition of GSK3, reduced the expression of endog-
enous PEPCK, G6Pase and IGFBP1 genes and also the
activity of the isolated thymine-rich insulin response ele-
ment (TIRE) found in these gene promoters [10,11]. In an
attempt to further characterise the GSK3 regulation of
PEPCK, G6Pase and IGFBP1 we assessed whether a target
for GSK3, namely C/EBPα, could regulate TIRE activity. In
the hepatocyte C/EBPα activity is linked to cAMP induc-
tion of genes, so insulin inhibition of C/EBPα could
explain repression of these genes by insulin. In this
model, phosphorylation of C/EBPα by GSK3 would have
to induce C/EBPα activity toward the TIRE. Interestingly,
C/EBPα overexpression had a repressive effect on TIRE
activity in the rat hepatoma H4IIE cells (Fig 1A), and the
repression was lost when the TIRE sequence was mutated
at two residues to produce an insulin insensitive sequence
(DM5 [42]; Fig 1A). Hence C/EBPα regulated the TIRE inBMC Molecular Biology 2006, 7:14 http://www.biomedcentral.com/1471-2199/7/14
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a sequence specific and insulin-like manner. However,
mutation of the GSK3-regulated residues on C/EBPα
(T222/T226/S230) to alanines (C/EBPα-AAA) did not
alter the ability of C/EBPα to repress TIRE activity (Fig
1A). One possibility is that the dephosphorylated form of
C/EBPα repressed the TIRE, and that the overexpressed C/
EBPα was not substantially phosphorylated by GSK3.
Consistent with this hypothesis, co-expression of an active
form of GSK3 reduced the effect of wild-type C/EBPα on
the TIRE (Fig 1B). Unfortunately, increased GSK3 activity
also blocked the repressive action of the C/EBPα-AAA (Fig
1B) clearly demonstrating that phosphorylation of T222/
T226/S230 was not required for the action of GSK3 on the
isolated TIRE in H4IIE cells. This data questioned the
functional importance of T222/T226 phosphorylation in
the regulation of C/EBPα activity.
C/EBPα phosphorylation in intact cells Figure 2
C/EBPα phosphorylation in intact cells. AD293 cells 
were transiently transfected with Flag-C/EBPα (10 µg) prior 
to incubation with CHIR99021 as indicated (A). Cell lysates 
were then subjected to Western Blotting with the antibodies 
as labelled. A representative immunoblot (of 2 two separate 
experiments) is given. (B) AD293 cells were transfected with 
Flag-C/EBPα (10 µg) plus GSK3α-V5 (10 µg) or pcDNA6 (10 
µg) prior to 24 h incubation with CHIR99021 (2 µM), lysis 
and Western Blot analysis. A representative immunoblot (of 
three separate experiments) is given. (C) H4IIE cells were 
infected with adenovirus expressing Flag-C/EBPα. After 16 h 
the infected cells were serum starved for 3 h prior to incuba-
tion with or without insulin (10 nM) or CHIR99021 (2 µM) 
for the times indicated. Cell lysates were immunoblotted 
with the antibodies indicated and a representative experi-
ment is provided.
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C/EBPα expression suppresses the BPl-TIRE-Luc reporter  activity in H4IIE cells, independently of the phosphorylation  status of T222/T226 Figure 1
C/EBPα expression suppresses the BPl-TIRE-Luc 
reporter activity in H4IIE cells, independently of the 
phosphorylation status of T222/T226. (A) H4IIE cells 
were transfected with BPl-TIRE-Luc (10 µg) or DM5-Luc (10 
µg) along with either pcDNA6 vector (1 µg), Flag-C/EBPα (1 
µg) or Flag-C/EBPα-AAA (1 µg). Subsequently, cells were 
incubated with or without 10 nM insulin for 20 h prior to 
lysis and luciferase assay. Results are presented as relative 
luciferase activity to the control (serum free) and are average 
± SEM (n = 3) from two independent experiments. (B) H4IIE 
cells were infected with adenovirus expressing either β-
Galactosidase (AD-βgal) or active GSK3β (Ad-GSK3 S9A) 
for 20 h prior to transfection as described in (A). Results are 
presented as relative luciferase activity to the control (serum 
free) and are average ± SEM (n = 6) from two independent 
experiments. *** p < 0.001 compared to control (ad-b-gal).
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GSK3 phosphorylates C/EBPα in intact cells
It was therefore important to establish whether T222 and
T226 were actually phosphorylated by GSK3 in intact
cells. Cells were transfected with wild-type and mutant C/
EBPα and total and phosphorylated C/EBPα visualised by
Western Blotting. T222/226 phosphorylation, measured
with this antibody, was clearly present in intact cells (Fig
2). Incubation with 1 or 2 µM of the GSK3 inhibitor
CHIR99021 [11,43] for 6 or 24 h significantly reduced the
phosphorylation of T222/226 of wild-type C/EBPα (Fig
2A), confirming that GSK3 was a T222/226 kinase in these
cells. At shorter incubations, 1 µM CHIR99021 was suffi-
cient to give maximal reduction in T222/226 phosphor-
ylation, while 2 µM had a greater effect at 24 h incubation.
This is similar to the effect of these concentrations on β-
catenin activation in the H4IIE cells [11]. Meanwhile, co-
expression of active GSK3α (Fig 2B) only produced a mar-
ginal induction of phosphorylation (around 1.2 fold) sug-
gesting that the expressed C/EBPα was either almost fully
phosphorylated at T222/226 or that it was not a particu-
larly good substrate for GSK3. Mutation of T222/226 to
alanines made the mutant C/EBPα unresponsive to the
phosphospecific antibody (see later). Interestingly, the
dephosphorylation of C/EBPα in H4IIE cells treated with
CHIR99021 was rapid, but not complete (Fig 2C). How-
ever, there was no significant reduction in T222/226
phosphorylation following up to 2 h incubation with
insulin (Fig 2C and Fig 3), even though insulin promoted
phosphorylation of Ser9/Ser21 of GSK3β and GSK3α
respectively. Insulin reduced GSK3 activity around 50% in
the H4IIE cell line but this is clearly not sufficient to
reduce T222/226 phosphorylation. Therefore it appears
that insulin does not regulate T222/226 phosphorylation
in these cells through inhibition of GSK3. However, the
data suggested that some level of T222/226 phosphoryla-
tion by GSK3 occurs on the overexpressed protein (Fig
2C).
C/EBPα phosphorylation in vitro Figure 4
C/EBPα phosphorylation in vitro. (A) Recombinant Flag-
C/EBPα (6 pmol) was generated by scission of the GST-C/
EBPα fusion protein and incubated with either recombinant 
GSK3β (2 U/ml) or p42 MAPK (10 U/ml) and [γ-32P]-ATP 
for 1, 10, 30, and 60 min. The reaction was stopped and sep-
arated by SDS-PAGE. (B) The stoichiometry of Flag-C/EBPα 
phosphorylation in (A) by either MAPK or GSK3β is quanti-
fied and presented. (C) GST-C/EBPα (7.5 pmol) was incu-
bated with recombinant GSK3β (2 U/ml) and ATP for 1, 10, 
30, and 60 min. The reaction was stopped and separated by 
SDS-PAGE and subjected to Western Blot analysis for phos-
pho-T222/226. The equivalent stoichiometry of phosphoryla-
tion (mol/mol) calculated in A is indicated above each band.
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C/EBPα is a relatively poor substrate for GSK3 in vitro
We next characterised C/EBPα phosphorylation by GSK3
in vitro (Fig 4). Incubation of C/EBPα with GSK3β for up
to one hour resulted in a slow incorporation of less than
0.03 mol phosphate per mol of protein (Fig 4A and 4B).
In comparison, p42MAP kinase phosphorylation of C/
EBPα increased over 60 min peaking around 1.5 mol per
mol (Fig 4A and 4B). Phosphorylation of C/EBPα by
p42MAP kinase did not occur at T222, T226 or S230 (see
below) and is more likely to be on S21 [44]. Interestingly
western blot analysis of C/EBPα following incubation
with GSK3β gave little indication of this slow increase in
phosphorylation, and a very strong signal was obtained
with the phosphospecific antibody even at low stoichiom-
etry of phosphorylation (Fig 4C). These data demon-
strated that C/EBPα was a relatively poor substrate for
GSK3 in vitro ,but that the phospho-T222/226 antibody
was highly sensitive. It is difficult to directly compare
phosphorylation of C/EBPα with other substrates of GSK3
as most are poorly phosphorylated prior to priming. For
example CRMP phosphorylation by GSK3 (under identi-
cal conditions to those used for C/EBPα in Fig 4) incorpo-
rates around 0.2 mol/mol phosphate within 2 h of
incubation [45]. However, this increases more than 5-fold
if the substrate is first primed. Of course we can never rule
out the possibility that an intrinsic factor improves the
GSK3-C/EBPα interaction in vivo ,either promoting prim-
ing at an unidentified residue or allowing greater phos-
phorylation by GSK3.
GSK3 phosphorylation of T222/226 in cells does not 
require S230 phosphorylation
Many substrates of GSK3 are primed for kinase recogni-
tion by prior phosphorylation at a S/T residue four amino
acids C-terminal to the target site [1]. S230 lies within this
'consensus' GSK3 targeting sequence (Table 2). Therefore
S230 phosphorylation could prime for T226 phosphor-
ylation by GSK3, permitting subsequent phosphorylation
of T222 by GSK3. However, mutation of S230 to alanine
had no effect on T222/226 phosphorylation in intact cells
(Fig 5). This argued that S230 phosphorylation did not
prime for T226 phosphorylation by GSK3 in resting cells,
or that the wild-type C/EBPα is not being efficiently phos-
phorylated at S230. Since the amino acid immediately fol-
lowing S230 is a proline (Table 2), we hypothesised that
priming may only occur after induction of a proline-
directed kinase such as a member of the MAP kinase fam-
ily. Therefore we attempted to induce S230 phosphoryla-
tion by incubation of cells with serum, which stimulates
the classical MAP kinase and several other proline-
directed kinases such as cyclin-dependent kinases. How-
ever, T222/226 phosphorylation of wild-type or S230A C/
EBPα was not altered in serum treated cells (Fig 5B),
despite activation of the p90RSK downstream of the p42/
p44MAP kinase (Fig 5B). This demonstrated we could not
alter S230 phosphorylation by incubating cells with or
without serum. Interestingly, serum treatment induced
phosphorylation of S21/9 of GSK3α/β (Fig 5B), suggest-
ing some inhibition of GSK3 occurs in the serum treated
cells. This was not sufficient to reduce C/EBPα phosphor-
ylation but did partially reduce glycogen synthase phos-
phorylation (a known substrate of GSK3 ([46]; Fig 5B).
Similarly, treatment of the cells with CHIR99021 did not
completely inhibit T222/226 phosphorylation (Fig 2 and
Fig 3), despite a complete loss of glycogen synthase phos-
phorylation (Fig 5B). Therefore T222/226 must be rela-
Table 2: Comparison of mouse, rat and human C/EBPα 
sequences surrounding potential GSK3 target residues. 
Numbers refer to mouse (upper) and human (lower) potential 
phosphorylated residues. C/EBPα sequences.
222 226 230
Mouse PGHPTPPPTPVPSPHAA
Rat PGHPTPPPTPVPSPHPA
Human PGHPTPPPTPVPSPHAA
226 230 234
Table 1: Primers and oligonucleotides used in C/EBP mutagenesis. Primers and oligonucleotides
Constructs DNA sequences
Flag-C/EBPα Forward: 5'-GGA TCC GCC ACC ATG GAC TAG AAG GAC GAC GAT GAC AAG GAG TCG GCC GAC TTC 
TAC GAG-3'
Reverse: 5'- GAA TTC TCA CGC GCA GTT GCC CAT GGC CTT GAC-3'
S230A Flag-C/EBPα mutant Sense: 5'-CGC CCG TGC CCG CCC CTC ATC CCG-3'
Antisense: 5'-CGG GAT GAG GGG CGG GCA CGG GCG-3'
Flag-C/EBPα mutant(AA) Sense:5'-GGC CAC CCT GCG CCG CCG CCG GCG CCC GTG CCC AGC CCT CAT CCC-3'
Antisense: 5'-GGG ATG AGG GCT GGG CAC GGG CGC CGG CGG CGG CGC AGG GTG GCC-3'
GSK3α-V5 Forward: 5'-GGA TCC GCC ACC ATG AGC GGC GGC GGG CCT T-3'
Reverse: 5'-TCT AGA GGA AGA GTT AGT GAG GGT AGG TGT GGCA-3'
CBE-Luc reporter Sense:5'-CGG GGT ACC CCG ATT TTT GCG CAA TTT TAT TGC GCA ATC AAT ATT GGA AGA TCT TC- 3'
Antisense: 5'-GAA GAT CTT CCA ATA TTG ATT GCG CAA TAA AAT TGC GCA AAA ATC GGG GTA CCC 
CG-3'BMC Molecular Biology 2006, 7:14 http://www.biomedcentral.com/1471-2199/7/14
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tively resistant to dephosphorylation or a distinct T222/
226 protein kinase must be present in these cells. Again,
potential substrates for GSK3 have been reported that
have their priming at a residue more distant from the
GSK3 target site, and we cannot discount that possibility.
However, our data strongly argues against priming
through S230 phosphorylation.
Prephosphorylation of CEBPα by p42 MAP kinase did not
prime for subsequent phosphorylation by GSK3 in vitro
(Fig 6A), confirming that S230 is not targeted by p42 MAP
kinase. Similarly, incubation of cells with either a
p42MAP kinase inhibitor (PD98059) or a p38MAP kinase
inhibitor (SB203580) had no effect on phosphorylation
of CEBPα at T222/226 (Fig 6B).
C/EBPα induced a consensus binding element while 
repressing the TIRE in H4IIE cells
In contrast to the repressive action on TIRE activity, over-
expression of C/EBPα in H4IIE cells induced the activity
of a consensus C/EBP binding element (CBE) (Fig 7A). We
were therefore able to investigate whether the GSK3 regu-
lation of T222/T226 was dependent on the DNA sequence
analysed. Mutation of T222/226/S230 to alanines (in any
combination) made no difference to the induction of the
CBE by C/EBPα (Fig 7A). Similarly, inhibition of GSK3
using CHIR99021 or insulin had no effect on CBE activity
(Fig 7A and 7B). Therefore GSK3 phosphorylation of
T222/226 does not regulate either induction of the CBE or
MAPK does not influence CEBPα phosphorylation by GSK3 Figure 6
MAPK does not influence CEBPα phosphorylation by 
GSK3. (A) Recombinant Flag-C/EBPα (6 pmol) was incu-
bated for 60 min with or without p42 MAPK (10 U/ml) and/
or GSK3β (2 U/ml) and Mg ATP, as indicated in figure. The 
reaction was stopped and separated by SDS-PAGE and sub-
jected to Western Blot. (B) AD293 cells were transfected 
with 10 µg of Flag-C/EBPα, Flag-C/EBPα-AA, or Flag-C/
EBPα-S230A prior to 24 h incubation with 10 µM PD98059, 
SB203580 or DMSO, lysis and Western Blot analysis. A rep-
resentative immunoblot of two such experiments is given.
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S230 phosphorylation does not prime for T226 phosphoryla- tion by GSK3 Figure 5
S230 phosphorylation does not prime for T226 phos-
phorylation by GSK3. (A) AD293 cells were transfected 
with 10 µg of Flag-C/EBPα, Flag-C/EBPα-AA, Flag-C/EBPα-
AAA or Flag-C/EBPα-S230A prior to 24 h incubation with 2 
µM CHIR99021 (CT), lysis and Western Blot analysis. A rep-
resentative immunoblot of two such experiments is given. 
(B) AD293 cells were transfected with 10 µg of Flag-C/EBPα 
or Flag-C/EBPα-S230A, then serum starved overnight prior 
to a 2 h incubation with CHIR99021 (2 µM) or 10%(v/v) FBS. 
Cell lysates were then subjected to Western Blotting with 
the antibodies as labelled. A representative immunoblot of 
two such experiments is given.
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repression of the TIRE in the H4IIE cells. Interestingly CBE
activity was induced in the presence of the synthetic glu-
cocorticoid dexamethasone to a similar level as that seen
with C/EBPα overexpression (Fig 7B).
C/EBPα overexpression does not regulate endogenous 
TIRE-containing genes
In order to establish whether changes in C/EBPα phos-
phorylation could alter expression of the insulin regulated
genes IGFBP1 and G6Pase, we overexpressed C/EBPα in
H4IIE cells using an adenoviral vector to produce almost
100% transfection efficiency (Figs 8, 9, 10). We observed
no effect of C/EBPα expression on IGFBP1 (Fig 8) or
G6Pase (Fig 9) gene expression, and no alteration in reg-
ulation of either gene by dexamethasone, insulin or
CHIR99021. However, there was a significant repression
of the co-expressed BP1-TIRE by C/EBPα when compared
with its effect on the insulin resistant TIRE (DM5) (Fig
10). This suggests that C/EBPα overexpression represses
the isolated element but has no effect on this element
when it is in the context of the intact gene promoters. This
is an example of the dangers of studying isolated pro-
moter elements and extrapolating to intact gene promot-
ers without examining endogenous regulation.
Interestingly, a postnatal knockout of C/EBPα resulted in
reduced basal expression of PEPCK and G6Pase but did
not alter regulation of these genes by cAMP [40]. Again,
Regulation of endogenous IGFBP1 gene expression in H4IIE  cells following C/EBPα overexpression Figure 8
Regulation of endogenous IGFBP1 gene expression in 
H4IIE cells following C/EBPα overexpression. H4IIE 
cells were infected with adenovirus expressing either β-
Galactosidase (AD-βgal) or Flag-C/EBPα (Ad-C/EBPα). 
Infected cells were serum starved overnight prior to a 3 h 
incubation with insulin (10 nM), dexamethasone (500 nM), 
CHIR99021 (CT, 2 µM), or a combination of each as indi-
cated. RNA was extracted and IGFBP1 expression was meas-
ured by RPA. Expression was calculated relative to 
cyclophilin mRNA levels. Data are presented as the average 
± SEM of three experiments, with a representative autoradi-
ograph shown in the upper panels.
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C/EBPα activity in H4IIE cells Figure 7
C/EBPα activity in H4IIE cells. (A) H4IIE cells were 
transfected with the CBE-Luc (10 µg) along with 1 µg of 
pcDNA6, Flag-C/EBPα, Flag-C/EBPα-AA, Flag-C/EBPα-AAA 
or Flag-C/EBPα-S230A prior to a 20 h incubation with insulin 
(10 nM) or CHIR99021 (CT, 2 µM). Results are presented as 
relative luciferase activity to control (serum free) and are 
average ± SEM (n = 6) from two independent experiments. * 
p = 0.0683, ** p = 0.0523. (B) H4IIE cells were co-transfected 
with 10 µg of either CBE-Luc reporter or pGL3-Luc reporter 
plus 1 µg of pcDNA6 or Flag-C/EBPα prior to 20 h incuba-
tion with dexamethasone (500 nM), insulin (10 nM), or 
CHIR99021 (CT, 2 µM). Results are presented as relative 
luciferase activity to the control (serum free) and are average 
± SEM (n = 6) from two independent experiments. ***p < 
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this would argue against a repressive effect of this factor
on the endogenous genes.
C/EBPα regulation of the CBE in preadipocytes is greater 
when T222/226 are mutated
C/EBPα has an important role in adipocyte differentiation
[37,47,48], therefore we transfected 3T3-L1 preadipocytes
with C/EBPα and measured CBE activity (Fig 11A). In
contrast to the H4IIE cells, mutation of T222/226 to
alanines resulted in a significant increase in transactiva-
tion potential compared to wild-type C/EBPα (Fig 11A).
This suggested that phosphorylation of these residues was
inhibiting C/EBPα activity in these cells. Consistent with
this hypothesis, inhibition of GSK3 using CHIR99021 or
insulin induced wild-type C/EBPα activity (Fig 11A). In
addition, the C/EBPα S230A mutant had similar transac-
tivation potential to the AA mutant (Fig 11A), strongly
suggesting that S230 was a priming site for T222/T226
phosphorylation in these cells. However we could find no
evidence that phosphorylation of T222/226 was reduced
in the S230A mutant (Fig 11B). Although there was a great
deal of inter-experiment variation in the phosphorylation
of T222/T226 in the WT and the S230A mutant there was
not a significant difference between the two, and in 2 out
of the three experiments the S230A mutant exhibited
higher phosphorylation than the WT protein (Fig 11B).
Therefore, changes in phosphorylation of these two sites
cannot account for the difference in C/EBPα activity when
the S230 site is mutated to alanine. Ideally it would be
beneficial to confirm these data on endogenous gene
expression in the adipocyte cell line, however these cells
do not transfect efficiently with the adenoviral constructs
making it impossible to examine their effect on endog-
enous genes.
Conclusion
In summary, C/EBPα is not the link between GSK3 and
the hepatic TIRE-containing gene promoters. However, C/
EBPα can regulate the TIRE, at least when overexpressed,
and the residues T222/226 and S230 all influence C/EBPα
function in preadipocytes. Interestingly we demonstrate
opposite effects of C/EBPα overexpression on TIRE and
CBE activity, and a tissue specific role for the T222/226
motif in this activity. Our data also provides further evi-
dence of the differences in transcription factor activity
when measured using isolated promoter elements as
opposed to intact gene promoters. During the course of
this study a regulation of C/EBPβ by GSK3 in adipocytes
Regulation of the isolated TIRE in H4IIE cells following C/ EBPα overexpression Figure 10
Regulation of the isolated TIRE in H4IIE cells follow-
ing C/EBPα overexpression. H4IIE cells, infected as in Fig. 
8, were also transfected with 10 µg of BPl-TIRE-Luc or DM5-
Luc and luciferase activity measured 20 h later. Results are 
presented as relative luciferase activity to the control (AD-
βgal, serum free) and are average ± SEM of three experi-
ments. ** p < 0.01 AD-βgal versus Ad-C/EBPα.
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Regulation of endogenous G6Pase gene expression in H4IIE  cells following C/EBPα overexpression Figure 9
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was reported [49]. Therefore it will be of interest to con-
firm whether this C/EBP isoform is the link between GSK3
inhibition and TIRE regulation in hepatocytes.
Methods
Material
Radioisotopes [γ-32P]ATP (Amersham Biosciences, Inc.,
Little Chalfont, Buckinghamshire, UK) and [α-32P]UTP
(ICN, Thame, Oxfordshire, UK) were purchased from the
indicated sources. Insulin was obtained from Novo Nord-
isk (Crawley, West Sussex, UK), dexamethasone and IBMX
(Sigma, Poole, Dorset, UK), RNAse Protection Assay Kit II
was from AMS Biotech/Ambion (Austin, TX, USA).
CHIR99021 was synthesised by Dr Rudolpho Marquez
[11]. Antibodies to the following epitopes were purchased
from the companies in parenthesis; C/EBPα (Santa Cruz
Biotechnologies, UK), phospho-C/EBPα (T222/226) and
phospho-GSK3α/β (S21/9) (Cell Signaling Technologies,
Hertfordshire, UK), Flag (Sigma, Poole, Dorset, UK),
while the Glycogen Synthase (total and site 3 phospho
antibody), and p90 RSK phospho antibody were made in
the Division of Signal Transduction Therapy, University of
Dundee.
Cell culture
The rat hepatoma cell line H4IIE was cultured in Dul-
becco's Modified Eagle's Medium (DMEM) containing
1000 mg/L glucose, 5% (v/v) foetal calf serum (GIBCO,
Carlsbad, CA). The AD293 cell line was maintained in
DMEM containing 4500 mg/L glucose, 10% (v/v) foetal
calf serum, while 3T3-L1 preadipocytes were grown in
DMEM containing 4500 mg/L glucose and 10% (v/v)
newborn calf serum (GIBCO).
Construction of plasmid DNA, luciferase reporter, and 
mutagenesis
The full length C/EBPα cDNA was amplified by PCR from
a rat L6 cDNA library and BamHI/Kosac/Flag and EcoRl
sequences introduced at the 5' and 3' end respectively as
indicated in Table 1. The PCR product was subcloned into
TOPO one shot (Invitrogen), verified by DNA sequencing,
and subcloned into pcDNA6, GST-pGEX-6, and pshuttle-
CMV vectors for the purpose of expression in mammalian
cells, production of recombinant GST-tagged protein in
Escherichia coli BL21 cells, and construction of recom-
binant adenovirus (AdEasy XL Adenoviral Vector System,
Stratagene), respectively. Flag-C/EBPα point mutants,
S230A, T222A/T226A (AA), and T222A/T226A/S230A
(AAA) were generated using the QuickChange mutagene-
sis kit (Stratagene) with the oligo sequences shown in
Table 1. The AAA mutant was generated by introducing
the S230A point mutation into the AA mutant. A luci-
ferase reporter construct containing a C/EBP consensus
binding sequence (CBE-Luc) 5' of a thymidine kinase pro-
moter was constructed using the oligos shown in Table 1.
Both sense and antisense oligos were annealed prior to
restriction digest with Kpnl and Bgl II. The product was
subcloned into the BP1 luciferase reporter linearised with
Kpnl and BamHI to remove the TIRE (the luciferase con-
Mutation of T222/226 and S230 alters C/EBPα activity in  preadipocytes Figure 11
Mutation of T222/226 and S230 alters C/EBPα activ-
ity in preadipocytes. A) 3T3L1 preadipocytes were trans-
fected with 2 µg of C/EBP-Luc reporter along with 200 ng of 
pcDNA6, Flag-C/EBPα, AA, AAA, or S230A as described in 
the material and methods. Cells were incubated with insulin 
(l00 nM) or CHIR99021 (CT, l0 µM) for 20 hr prior to har-
vest for luciferase assay. Results are relative luciferase activity 
and are average ± SEM (n = 6) from two independent exper-
iments. * p < 0.05, ** p < 0.01, *** p < 0.005 compared with 
control. B) 3T3L1 preadipocytes were transfected with 200 
ng of pcDNA6, Flag-C/EBPα wild type, or Flag-C/EBPα 
S230A, ± 2 µM CHIR99021 (CT). Cells were lysed, the 
recombinant protein immunoprecipitated using anti-FLAG, 
and visualised using anti-FLAG or anti-phospho222/226. A 
representative experiment is shown in the upper panel, while 
a quantification of three such experiments is given in the 
lower panel.
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struct was a gift from Dr Robert Hall and Professor Daryl
K. Granner (Vanderbilt University, TN, USA)).
Transient transfection
AD293 cells were transiently transfected with 10 µg of
pcDNA6, Flag-C/EBPα, AA, AAA, or S230A mutants by the
calcium phosphate method. DNA precipitant was added
to cells for 4 h, prior to addition of inhibitors and hor-
mones at the concentrations and for the times indicated in
figure legends.
H4IIE cells were transfected as described previously [50].
Briefly, 10 µg of BP1-TIRE-Luc, the insulin insensitive
point mutant of the TIRE (DM5-Luc), C/EBP-Luc, or
pGL3-Luc (control), along with 1 µg of pcDNA6, wild
type or mutant Flag-C/EBPα constructs were precipitated
and incubated with H4IIE cells in suspension. Cells were
plated onto 10 cm dishes, allowed to attach for 4 h, prior
to DMSO shock and incubation with hormones/inhibi-
tors for 20 h as indicated in figure legends. Cells were
lysed in 200 µl lysis buffer (Promega, UK), the cell debris
removed by centrifugation at 13,000 × g for 10 min at
4°C, and the supernatant stored at -70°C. Luciferase
assays were performed using the firefly luciferase assay
system (Promega, UK), according to manufacturer's
instructions, with luciferase activity being corrected for
the protein concentration in the cell lysate.
3T3-L1 preadipocytes were transfected using Fugene 6
Transfection Reagent (Roche) following manufacture's
protocol. C/EBP-Luc (2 µg) along with 200 ng of pcDNA6,
wild type or mutant Flag-C/EBPα constructs was com-
plexed with Fugene 6 transfection reagent prediluted in
Serum Free DMEM at the ratio of 1:3 (µg DNA : µl Fugene
6) for 20 min at RT before addition to cells. After 4 h at
37°C an equal amount of DMEM containing 20% foetal
calf serum was added. 48 h post-transfection, cells were
washed with serum free DMEM and incubated for a fur-
ther 24 h in serum free media with or without hormones
or inhibitors as described in figure legends. Cells were
lysed in 100 µl lysis buffer and luciferase activity deter-
mined as above.
We estimate that the level of over expression of C/EBPα is
roughly 4 fold in the adipocytes, around 6-fold in the liver
cells by transient transfection and nearly 10 fold in aden-
ovirally infected H4IIE experiments
In vitro phosphorylation of C/EBPα
Purified recombinant C/EBPα (6 pmol) was incubated at
30°C with His6-GSK3β (2 U/ml) or p42 MAPK (10 U/ml),
10 mM magnesium acetate, 0.1 mM [γ-32P]ATP (450,000
cpm/nmol) in buffer containing 50 mM Tris-HCl, pH 7.5,
0.03% (v/v) Brij 35, and 0.1% (v/v) 2-mercaptoethanol,
for times indicated in the figure legends. Reactions were
stopped by the addition of LDS containing sample buffer
(Novex), heated at 70°C for 10 min and subjected to SDS-
PAGE. The gel was dried on the 3 M Filterpaper, and radi-
oactivity incorporated into recombinant C/EBPα visual-
ized by autoradiography and quantified by
phosphorimager (Fuji). A standard curve of radiolabelled
ATP was used to assess nmoles of phosphate incorporated
into the C/EBPα substrate. p42 MAP kinase and GSK3
activities were calculated by in vitro phosphorylation of
myelin basic protein and P-GS peptide, respectively.
Preparation of cell extract for SDS PAGE and 
Immunoblotting
Cells were washed with ice cold PBS twice and scraped
into ice-cold lysis buffer (25 mM Tris/HCl, pH 7.4, 50 mM
NaF, 100 mM NaCl, 1 mM sodium vanadate, 5 mM EGTA,
1 mM EDTA, 1% (v/v) Triton X-100, 10 mM sodium pyro-
phosphate, 1 mM benzamidine, 0.1 mM PMSF, 0.27 M
sucrose, 2 µM microcystin and 0.1% (v/v) 2-mercaptoeth-
anol). Cell debris was removed by centrifugation at
13,000 × g for 10 min at 4°C. Preparation of nuclear pro-
tein extracts was performed using a Nuclear Extraction Kit
(Panomics), as per the manufacture's instructions. The
protein concentration was determined by Bradford assay
(Sigma), using BSA as standard as per the manufacture's
instructions. Protein from cell lines (10–20 µg from
H4IIE, 50 µg from AD293 or 3T3 preadipocytes) was sep-
arated on Novex SDS 4–12% polyacrylamide gels. Follow-
ing transfer to nitrocellulose, blots were blocked with 5%
(w/v) non-fat milk in TBST (Tris-buffered saline contain-
ing 0.1% (v/v) Tween 20) for 1 h, and incubated with pri-
mary antibodies at 4°C overnight prior to incubation for
1 h at RT with the secondary antibody and development
using ECL kit (Amersham Biosciences, Inc.).
Adenoviral Infection, RNA extraction and RNAse 
protection assay
For RNA studies, H4IIE cells were infected with recom-
binant adenovirus expressing Flag-C/EBPα (Ad-C/EBPα)
or β-Galactosidase (Ad-β-gal) for 4 h at MOI = 50. 24 h
later, infected cells were split into 10 cm dishes and serum
starved overnight prior to treatment with hormone/inhib-
itor for 3 h at the concentrations indicated in the figure
legends. Total cellular RNA was isolated using TRI Reagent
(Sigma) following the manufacturer's instructions. An
RNase Protection Assay (RPA) was performed to deter-
mine the relative amounts of IGFBP-1, G6Pase, and cyclo-
philin mRNA as described previously [50]. Band intensity
was quantified on a phosphorimager (Fuji), data calcu-
lated as a ratio of IGFBP-1 to cyclophilin mRNA. For phos-
phorylation studies, H4IIE cells were infected with
recombinant adenovirus expressing Flag-C/EBPα (Ad-C/
EBPα) at MOI = 100. 16 h later, infected cells were serum
starved for 3 h prior to treatment with hormone/inhibitorBMC Molecular Biology 2006, 7:14 http://www.biomedcentral.com/1471-2199/7/14
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for the times and at the concentrations indicated in the
figure legends.
Statistics
The comparison of one variable between two groups was
determined by unpaired Student's t-test with the aid of
PRISM 3.0 (Graphpad Software, USA) and/or Microsoft
Excel. The values were expressed as mean ± S.E.M.
Abbreviations
PEPCK; Phosphoenolpyruvate Carboxykinase, IGFBP1;
IGF binding protein-1, G6Pase; glucose-6-phosphatase,
RPA; RNAse Protection Assay, TIRE; thymine rich insulin
response element, C/EBP; CAAT enhancer binding pro-
tein, CBE; C/EBP binding element.
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